Development and characterization of NILK-2301, a novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancers (Statistics)

Development and characterization of NILK-2301, a novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancers

Anja Seckinger^1† , Sara Majocchi^2† , Valéry Moine², Lise Nouveau ², Hoang Ngoc³, Bruno Daubeuf2, Ulla Ravn², Nicolas Pleche², Sebastien Calloud², Lucile Broyer², Laura Cons², Adeline Lesnier², Laurence Chatel², Anne Papaioannou², Susana Salgado-Pires², Sebastian Krämer4, Ines Gockel⁴, Florian Lordick⁵, Krzysztof Masternak², Yves Poitevin², Giovanni Magistrelli², Pauline Malinge², Limin Shang², Sonja Kallendrusch^3,6, Klaus Strein¹ and Dirk Hose^1*

Light Chain Bioscience and partner LamKap Bio are proud to publish the preclinical findings on the CEACAM5xCD3 T cell engager, NILK-2301, Co-authored by A. Seckinger, S. Majocchi, the manuscript describes the development of the bispecific antibody generated on LCB's proprietary Kappa-Lambda Body platform, to support the immunotherapy approach for the treatment of CEACAM5-expressing cancers. LCB will Sponsor the clinical development of NILK-2301 with expected entry into patients early 2024.

Read full article : Abstract

Published: 12 December 2023│volume16, Article number: 117(2023)